Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents OH, (C_{1-5}) alkoxy, NH_2, NH-C_{1-5}-alkyl, or N(C_{1-5} alkyl)$_2$;

R_1 is a residue derived from any of the amino acid Phe, Tyr, or Trp~~, or Pro,~~ each of which may optionally be substituted by a (C_{1-5}) alkoxy groups, a (C_{1-5}) alkyl group or a halogen atom, ~~and~~ or a residue derived from Ala, Val, Leu, or Ile;

R_2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, ~~Pro~~, Glu, Gln, ~~pGlu~~, Asp, Leu or Asn;

R_3-and R_4 independently represent H, OH, (C_{1-5}) alkyl, or (C_{1-5}) alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5}) alkoxy;

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy;

and wherein R_0 represents a group of the formula



wherein Y represents -CO-, $-CH_2CO-$, $-CH_2CH_2CO-$,$-CH_2CH_2CH_2CO-$, -CH=CH-CO or -OCH_2CO-, and wherein Z represents a halogen atom, a trifluormethyl group, (C_{1-4}) alkoxy group, (C_{1-4}) alkyl group; or wherein two neighbouring substituents may form a (C_{1-3}) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The method according to claim 1, wherein R1 is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5})alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (Previously presented) The method according to claim 2, wherein R1 is a residue derived from Phe which may optionally be substituted by a (C_{1-5}) alkoxy groups, a (C_{1-5}) alkyl group or a halogen atom.

4. (previously presented) The method according to claim 1, wherein X is (C_{1-5})alkoxy, NH_2, NH-C_{1-5}-alkyl, or N(C_{1-5} alkyl)$_2$.

5. (previously presented) The method according to claim 1, wherein R2 is a residue derived from the amino acid Gly or Ile.

6. (previously presented): The method according to claim 1, wherein R_0 is a cinnamoyl moiety.

7. (previously presented): The method according to claim 1, wherein the compound of formula (I) is a cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.